Fractional
Leadership
Deep Domain
Expertise
De-risk Commercialization
Clarity AI HITL Commercial Workflow
Experienced Leadership
Team
Breakthroughs are only the beginning. In today’s complex health ecosystem, even well-funded, evidence-backed innovations face daunting barriers to commercialization.
1. Lacking Commercial Talent
Most startups fail to scale due to talent gaps
Proof: CB Insights, Upsilon IT, LinkedIn (2025)
​
2. No Reimbursement
Payers don’t support new products fast enough
Proof: 71% lack payer coverage at launch (AdvaMed 2024)
​
3. High Burn Rate
Development costs drain runway too quickly
Proof: $2.3B–$2.9B median drug development cost (Tufts CSDD 2024)
​
4. Failed Clinical Adoption
Solutions don't fit into care delivery
Proof: 70–90% of projects fail to integrate into hospital workflows (Forbes 2024, Healthcare Dive 2025)
​
5. Time-to-Revenue Crisis
Revenue lag leaves companies vulnerable
Proof: 18–24 months to reach Medicare coverage (Health Affairs 2024)
​
6. Regulatory Bottlenecks
Approval pathways are slower than innovation
Proof: IVDR adds 13–24 months to timelines (MedTech Dive, EU Commission)
​
We tackle the root causes of failure through a de-risked, AI-enabled approach designed to improve commercialization performance.
Industry benchmarks reveal:
-
97% of digital health startups fail to scale
-
90% of clinical-stage programs never reach market
-
67% of pharmaceutical launches miss revenue targets
At Strategic Growth AI, we apply a tailored commercialization framework designed to reduce execution risk by up to 60%, focusing on the structural gaps that drive failure. While real-world results vary based on therapeutic area, regulatory complexity, and market readiness, our integrated approach has consistently enhanced launch preparedness, stakeholder alignment, and speed to market.
See our Success Stories and Case Study
​​
🔹Up to 7x ROI
Work with healthcare specialists backed by research, financial modeling, and system data
Sources: PMC, NHS, BMC, Deloitte, Markets & Markets
​
🔹Up to 60% Less Risk
Our De-Risking Model cuts scientific, commercial, and financial risk using predictive analytics and Monte Carlo planning.
​
🔹Up to 34% Faster to Market
Our milestone approach accelerates launch by 30–34%, backed by modeling and optimization data
​
🔹Avoid Up to 30% in Costs
We apply TDABC and scenario planning to help you skip avoidable costs in GTM, regulatory, and ops
​
🔹Clarity AI Intelligence Framework
Faster, smarter decisions with AI and expert oversight.
🔹Evidence-Based Strategy
Every move is backed by peer-reviewed data, NHS-grade modeling, and proven healthcare methodologies
​
🔹Investor-Grade Forecasting
IRR, PoS, rNPV, MOIC, we speak the language of investors and boards using validated financial models
​
🔹Built for Your Stage
Startups, SMBs, enterprises, or investors, our method adapts to your goals, risk profile, and growth phase
​
Disclaimers: Results may vary based on organization, implementation, and baseline conditions. Percentage improvements represent potential based on established methodologies and optimization studies​
​
​
Reduce Risk by up to 60%
From Lab to Launch to Liquidity
Pharma | Biotech | MedTech | Diagnostics | AI‑Health​
​
Book Your Free Strategy Call
Professional Affiliations
UBC Entrepreneurship • BC Tech • AIinBC • Life Sciences BC